secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001213900-23-036112
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara reports Q1 net loss $9.0M; plans Phase 2 trials for TARA-002 in NMIBC and LMs
--------------------------------------------------------------------------------

- Cash, equivalents and restricted cash $89.5M at March 31, 2023; funding expected into 2025.
- Net loss $9.0M ($0.80/sh) vs $10.8M ($0.96) in Q1 2022; R&D $5.1M, G&A $4.6M.
- Positive preliminary data: TARA-002 well tolerated; tumor regression in all 3 evaluable CIS patients, including a CR in a BCG-unresponsive patient.
- ADVANCED-2 Phase 1b/2 trial in up to 102 CIS patients planned for 2H23; STARBORN-1 Phase 2 in pediatric LMs cleared by FDA, start Q4 2023.
- IV Choline Chloride IFALD prospective study ongoing; results expected Q3 2023, then regulatory feedback.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390023036112/0001213900-23-036112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390023036112/ea177795-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-036112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer